Aandelen in “Gezondheidstechnologie”

Aandeel Datum Koers Evolutie
vlag Qiagen NV 24/10 49,320 USD
-0,06% 		-0,06%
vlag Qualigen Therapeutics Inc 24/10 3,640 USD
+3,12% 		+3,12%
vlag Quanterix Corp 24/10 5,720 USD
-2,39% 		-2,39%
vlag Quantum Genomics 24/10 0,072 EUR
-1,77% 		-1,77%
vlag Quest Pharmatech, Inc. 21/10 0,040 CAD
0,00% 		0,00%
vlag QuidelOrtho Corp. 24/10 30,510 USD
+2,38% 		+2,38%
vlag Quince Therapeutics Inc 24/10 1,760 USD
-1,12% 		-1,12%

Nieuws over “Gezondheidstechnologie”

09:00 · De week die komt: Trump en Xi, Magnificent 7, Nederland, AB InBev, Argenx, ECB, Fed en Egypte · Tijd.be (€)

De week die komt: Trump en Xi, Magnificent 7, Nederland, AB InBev, Argenx, ECB, Fed en Egypte

09:00 · De week die komt: Trump en Xi, Magnificent 7, Nederland, AB InBev, Argenx, ECB, Fed en Egypte · Tijd.be (€)

Hoe verloopt de ontmoeting tussen Donald Trump en Xi Jinping? Hoe verliep het kwartaal voor AB InBev, Argenx en Melexis? Kunnen de Magnificent 7 de torenhoge beloftes blijven waarmaken? Wie wint de Ne...

04:42 · Cytokinetics Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK · Persbericht

00:32 · Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies · Persbericht

24/10 · Eindspel op het Galapagos-eiland · Tijd.be (€)

Met de liquidatie van zijn celtheraptietak is Galapagos verveld tot een beursgenoteerde bankrekening. Een plan om die 3,1 miljard euro cash strategisch aan het werk te zetten is er echter niet. Spreke...

24/10 · CARBIOS announces the publication of its Interim report for the first half of 2025 · Persbericht

24/10 · Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety · Persbericht

24/10 · Baxter International, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - BAX · Persbericht

24/10 · Class Action Filed Against Cytokinetics, Incorporated (CYTK) - November 17, 2025 Deadline to Join - Contact Levi & Korsinsky · Persbericht

24/10 · Lantheus Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 10, 2025 to Discuss Your Rights - LNTH · Persbericht

24/10 · Shareholders that lost money on Semler Scientific, Inc.(SMLR) should contact Levi & Korsinsky about pending Class Action - SMLR · Persbericht

24/10 · Class Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors - Contact Levi & Korsinsky · Persbericht

24/10 · Shareholders that lost money on Semler Scientific, Inc.(SMLR) should contact Levi & Korsinsky about pending Class Action - SMLR · Persbericht

24/10 · First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine · Persbericht

24/10 · Lilly to Acquire Adverum Biotechnologies · Persbericht

24/10 · Lilly to Acquire Adverum Biotechnologies · Persbericht

24/10 · Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis · Persbericht

24/10 · Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio · Persbericht

24/10 · Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial · Persbericht

24/10 · Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis · Persbericht

24/10 · Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial · Persbericht

Mijn selecties